Boston Therapeutics' Affiliate Advance Pharmaceutical Company Progresses with BTI-320 Clinical Trial

Boston Therapeutics (OTCQB:BTHE) announces that Advance Pharmaceutical Company is midway through enrolling subjects in newly launched critical trial to evaluate BTI-320 in pre-diabetic individuals. The trial is being carried out at The Chinese University of Hong Kong.
As quoted in the press release:

This key developmental trial and the associated endpoints are pivotal for concluding the BTI-320 registration in mainland China. The pivotal trial for product registration will enter the final phase for registration through testing this month July 2015. The clinical trial is planned to be completed by year end and the overall dossier for approval is targeted to be submitted in January 2016 for pending country wide approval in the first half of 2016. BTI-320 is planned to address and benefit a population of more than 350,000,000 million who are pre-diabetic and could make a significant contribution to controlling healthcare costs.

CEO of Boston Therapeutics, David Platt, comments:

We are pleased to enjoy this collaborative effort with APC and add to the beneficial effects of BTI-320 on people in China who are pre-diabetic, a population that is estimated to be more than three times the size of the known diabetes population. We are confident we will collect key information as a result of this study. We are fortunate to have APC as a financial partner to conduct and fund these and other studies and look forward to commercializing BTI-320 where we may help people to manage this world health mandate to manage blood sugar.

Click here to read the full press release.